Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Number of holders
-
81
-
Total 13F shares, excl. options
-
113,574,015
-
Shares change
-
-1,837,631
-
Total reported value, excl. options
-
$425,913,139
-
Value change
-
-$9,027,809
-
Put/Call ratio
-
126%
-
Number of buys
-
25
-
Number of sells
-
-52
-
Price
-
$3.75
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q4 2021
107 filings reported holding ADAPY - Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share as of Q4 2021.
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) has 81 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 113,574,015 shares
of 1,571,428,571 outstanding shares and own 7.23% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (38,974,185 shares), NEA Management Company, LLC (17,082,611 shares), BAILLIE GIFFORD & CO (13,756,352 shares), BAKER BROS. ADVISORS LP (9,830,877 shares), Capital World Investors (8,002,700 shares), PFM Health Sciences, LP (3,201,066 shares), MORGAN STANLEY (2,243,423 shares), Rock Springs Capital Management LP (2,215,588 shares), Long Focus Capital Management, LLC (2,162,313 shares), and MILLENNIUM MANAGEMENT LLC (1,643,478 shares).
This table shows the top 81 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.